Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Separately, Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Cellectis Price Performance

Shares of NASDAQ:CLLS opened at $1.58 on Wednesday. The company’s fifty day moving average is $1.65 and its two-hundred day moving average is $1.92. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12-month low of $1.41 and a 12-month high of $3.38. The company has a market cap of $87.54 million, a P/E ratio of -1.21 and a beta of 3.06.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares during the last quarter. B Group Inc. acquired a new position in Cellectis in the 4th quarter worth $5,547,000. Finally, Millennium Management LLC bought a new stake in Cellectis during the 4th quarter worth about $962,000. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.